The document discusses the challenges of pharmacovigilance. It outlines that pharmacovigilance aims to detect, assess, understand and prevent adverse drug reactions. However, there are challenges in detecting ADRs given limitations of preclinical data and changing drug use. Additional challenges include assessing ADRs, obtaining timely reporting from drug sponsors, and standardizing processes across organizations. The document calls for more education of healthcare professionals and patients about drug safety reporting to address gaps in pharmacovigilance.